Myles Cockburn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Myles Cockburn has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Christopher C. DeVoe
Department of Environmental and Occupational Health, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado
13 shared publications - David R. Johnson
Computing Ph.D. Program, Boise State University, Boise, ID 83725, USA
13 shared publications - Debashis Ghosh
Department of Biostatistics & Informatics, University of Colorado-Anschutz Medical Campus , Aurora, Colorado
13 shared publications - Lisa M. McKenzie
Department of Environmental and Occupational Health, and
13 shared publications - William B. Allshouse
Department of Environmental and Occupational Health
13 shared publications - Amy M. Berkman
Department of Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
7 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- p. 1-19
Mapping Ethnic Enclaves for Health Disparities Research: A Hybrid Clustering Approach
Ethnic enclaves, as an area-level social determinant of health, have significant implications for understanding ethnic health disparities. While a growing body of literature examines the impacts of residing in ethnic enclaves on the health of co-ethnics, studies often map enclaves solely from population concentrations within individual census tract. This approach overlooks the spatial clustering of populations in adjacent census tracts and the presence of cultural resources like ethnic-specific businesses and organizations. We develop and assess a hybrid clustering enclave model (HCEM) that maps spatial clustering patterns of both ethnic populations and cultural resources. We apply this approach to identify Chinese, Japanese, and Korean enclaves in Los Angeles County and compare the resulting ethnic enclaves to those mapped only from thresholds of ethnic population concentrations in individual census tracts. Depending on the types of health disparities assessed and the specific ethnicity of the enclave being mapped, different approaches to mapping Asian ethnic enclaves yield areas with larger or smaller health disparities than tracts mapped from population thresholds. Our results highlight the importance of aligning ethnic enclave measures with its conceptualization and potential health mechanisms when examining enclaves’ health impacts. We offer an approach to make and assess maps which may help researchers to capture the multidimensional features of enclaves and to distinguish diverse types of enclaves for answering a range of specific questions about the role of place in ethnic health disparities.
- 10 July 2026
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- p. 1-19
Open AccessMapping Ethnic Enclaves for Health Disparities Research: A Hybrid Clustering Approach
Ethnic enclaves, as an area-level social determinant of health, have significant implications for understanding ethnic health disparities. While a growing body of literature examines the impacts of residing in ethnic enclaves on the health of co-ethnics, studies often map enclaves solely from population concentrations within individual census tract. This approach overlooks the spatial clustering of populations in adjacent census tracts and the presence of cultural resources like ethnic-specific businesses and organizations. We develop and assess a hybrid clustering enclave model (HCEM) that maps spatial clustering patterns of both ethnic populations and cultural resources. We apply this approach to identify Chinese, Japanese, and Korean enclaves in Los Angeles County and compare the resulting ethnic enclaves to those mapped only from thresholds of ethnic population concentrations in individual census tracts. Depending on the types of health disparities assessed and the specific ethnicity of the enclave being mapped, different approaches to mapping Asian ethnic enclaves yield areas with larger or smaller health disparities than tracts mapped from population thresholds. Our results highlight the importance of aligning ethnic enclave measures with its conceptualization and potential health mechanisms when examining enclaves’ health impacts. We offer an approach to make and assess maps which may help researchers to capture the multidimensional features of enclaves and to distinguish diverse types of enclaves for answering a range of specific questions about the role of place in ethnic health disparities.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Figure 2 shows overall 5-year survival curves by subsequent malignant neoplasm (SMN) type from SMN diagnosis among those with primary adolescent and young adult (AYA) (a) female breast cancer, (b) cervical/uterine cancer, (c) Hodgkin lymphoma who were diagnosed between 1998 and 2020 (California Cancer Registry Data). Shaded areas represent 95% confidence intervals.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Figure 2 shows overall 5-year survival curves by subsequent malignant neoplasm (SMN) type from SMN diagnosis among those with primary adolescent and young adult (AYA) (a) female breast cancer, (b) cervical/uterine cancer, (c) Hodgkin lymphoma who were diagnosed between 1998 and 2020 (California Cancer Registry Data). Shaded areas represent 95% confidence intervals.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Table 2 shows treatments received by subsequent malignant neoplasm status.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Table 2 shows treatments received by subsequent malignant neoplasm status.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Background:Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized.Methods:Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry (n = 251,632). Pearson’s χ2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN.Results:A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither.Conclusions:Lung SMN has a long latency and high mortality among survivors of AYA cancer.Impact:More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Background:Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized.Methods:Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry (n = 251,632). Pearson’s χ2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN.Results:A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither.Conclusions:Lung SMN has a long latency and high mortality among survivors of AYA cancer.Impact:More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Figure 1 shows the cumulative incidence over time of developing subsequent malignant neoplasm (SMN) among survivors of primary adolescent and young adult (AYA) (a) female breast cancer who developed lung (n = 112) and non-lung (n = 4,971) SMN, (b) cervical/uterine cancer who developed lung (n = 95) and non-lung (n = 1,451) SMN, (c) Hodgkin lymphoma who developed lung (n = 70) and non-lung (n = 1,129) and who were diagnosed with a primary cancer between 1998 and 2020 (California Cancer Registry Data).
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Figure 1 shows the cumulative incidence over time of developing subsequent malignant neoplasm (SMN) among survivors of primary adolescent and young adult (AYA) (a) female breast cancer who developed lung (n = 112) and non-lung (n = 4,971) SMN, (b) cervical/uterine cancer who developed lung (n = 95) and non-lung (n = 1,451) SMN, (c) Hodgkin lymphoma who developed lung (n = 70) and non-lung (n = 1,129) and who were diagnosed with a primary cancer between 1998 and 2020 (California Cancer Registry Data).
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Table 3 shows vital status and cause of death by subsequent malignant neoplasm status.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Table 3 shows vital status and cause of death by subsequent malignant neoplasm status.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Table 1 shows the frequency of subsequent malignant neoplasms after primary cancer.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Table 1 shows the frequency of subsequent malignant neoplasms after primary cancer.
- 24 June 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (9) , 1618-1626
Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Background: Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized. Methods: Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry (n = 251,632). Pearson’s χ2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN. Results: A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither. Conclusions: Lung SMN has a long latency and high mortality among survivors of AYA cancer. Impact: More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
- 24 June 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (9) , 1618-1626
Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Background: Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized. Methods: Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry (n = 251,632). Pearson’s χ2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN. Results: A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither. Conclusions: Lung SMN has a long latency and high mortality among survivors of AYA cancer. Impact: More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Exposures from Oil and Gas Development and Childhood Leukemia Risk in Colorado: A Population-Based Case–Control Study
Populations to consider when developing epidemiological studies and O&G policies
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Exposures from Oil and Gas Development and Childhood Leukemia Risk in Colorado: A Population-Based Case–Control Study
Populations to consider when developing epidemiological studies and O&G policies
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Exposures from Oil and Gas Development and Childhood Leukemia Risk in Colorado: A Population-Based Case–Control Study
Study population exposure distributions between IA-IDW exposure groups within 16-km buffer by case-control status and exposure window (451 cases and 2,706 controls)
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Exposures from Oil and Gas Development and Childhood Leukemia Risk in Colorado: A Population-Based Case–Control Study
Study population exposure distributions between IA-IDW exposure groups within 16-km buffer by case-control status and exposure window (451 cases and 2,706 controls)